Background
Laboratory studies suggest that urinary uromodulin, the most common protein in the urine of healthy adults, may protect against urinary tract infection (UTI). Epidemiological studies evaluating this relationship in humans are lacking.
Study Design
Prospective longitudinal cohort study.
Setting & Participants
953 participants enrolled in the Cardiovascular Health Study.
Predictor
Uromodulin assayed using ELISA in spot urine samples.
Outcomes
Composite of outpatient UTI events or UTI-related hospitalizations and each of them individually identified using ICD-9 codes using negative binomial regression with robust standard errors adjustment for age, race, sex, body mass index, diabetes, eGFR, urinary albumin and urinary creatinine.
Results
The median uromodulin level was 25.9 (IQR, 17.3-38.9) μg/ml, the mean age of participants was 78 years, 61% were women, and 15% were Black. There were 331 outpatient UTI events and 87 UTI related hospitalizations among 186 participants over a median 9.9 years of follow up. Persons in the highest quartile (>38.93 μg/ml) of uromodulin concentration had a significantly lower risk of composite outcome (incidence rate ratio [IRR], 0.47; 95% CI, 0.29-0.79) compared to those in the lowest quartile (≤17.26 μg/ml). This association remained significant for outpatient UTI events (highest versus lowest quartile even after excluding those with prior UTI: IRR, 0.42; 95% CI, 0.23-0.77). The direction of association with UTI hospitalization was similar, but not statistically significant (IRR, 0.78; 95% CI, 0.39-1.58).
Limitations
Use of ICD-9 codes to identify outcomes and lack of generalizability to younger populations.
Conclusions
High urinary uromodulin levels are associated with a lower risk of UTI in older community dwelling adults independent of traditional UTI risk factors. This finding supports prior laboratory data indicating a protective role of uromodulin against UTI. Further research is needed to understand if this may lead to new treatments to prevent or treat UTI.